Medline (NASDAQ:MDLN) Stock Price Expected to Rise, Citigroup Analyst Says

Medline (NASDAQ:MDLN) had its price target lifted by analysts at Citigroup from $45.00 to $47.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup‘s price objective suggests a potential upside of 18.21% from the company’s previous close.

MDLN has been the topic of a number of other reports. BTIG Research reissued a “buy” rating and set a $55.00 price target on shares of Medline in a report on Thursday. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on shares of Medline and gave the company a “hold” rating in a report on Thursday, August 6th. BMO Capital Markets reiterated an “outperform” rating and issued a $47.00 price objective on shares of Medline in a research report on Thursday, August 6th. Leerink Partners upped their price objective on shares of Medline from $43.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Wells Fargo & Company lowered their target price on shares of Medline from $45.00 to $34.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 11th. Twenty-three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.85.

Medline Stock Performance

NASDAQ:MDLN traded down $0.59 during trading hours on Thursday, reaching $39.76. The company had a trading volume of 14,219,583 shares, compared to its average volume of 7,779,503. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. Medline has a 1-year low of $31.37 and a 1-year high of $50.88. The business’s 50 day moving average price is $34.58 and its 200-day moving average price is $39.53. The firm has a market cap of $52.27 billion and a PE ratio of 50.33.

Medline (NASDAQ:MDLN) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion for the quarter. Research analysts forecast that Medline will post 1.49 EPS for the current year.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total value of $90,884,814.65. Following the sale, the insider owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This trade represents a 11.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders sold 8,538,960 shares of company stock worth $302,807,442. Company insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Medline

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mass General Brigham Inc lifted its holdings in Medline by 167.6% during the first quarter. Mass General Brigham Inc now owns 70,357 shares of the company’s stock valued at $3,131,000 after purchasing an additional 44,063 shares in the last quarter. Andra AP fonden acquired a new stake in shares of Medline in the second quarter valued at about $3,180,000. Cetera Investment Advisers grew its position in shares of Medline by 128.4% in the first quarter. Cetera Investment Advisers now owns 52,088 shares of the company’s stock valued at $2,318,000 after purchasing an additional 29,282 shares during the period. Baird Financial Group Inc. increased its stake in shares of Medline by 1,151.5% during the second quarter. Baird Financial Group Inc. now owns 379,944 shares of the company’s stock worth $14,985,000 after purchasing an additional 349,584 shares in the last quarter. Finally, WINTON GROUP Ltd increased its stake in shares of Medline by 1,263.0% during the second quarter. WINTON GROUP Ltd now owns 367,057 shares of the company’s stock worth $14,477,000 after purchasing an additional 340,127 shares in the last quarter.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, above the $0.32 consensus, on revenue of $7.86 billion. Coverage also points to raised full-year growth expectations and a planned $1 billion share buyback. Medline Q3 earnings and outlook Q3 beat and buyback
• Positive Sentiment: Analysts reinforced a bullish outlook: BTIG reiterated Buy with a $55 target, Leerink Partners raised its target to $46 and rated the stock Outperform, and Barclays also issued a Buy rating. BTIG rating Leerink Partners target Barclays rating
• Neutral Sentiment: Medline plans price increases in 2027 to help offset inflation. This could support margins, though the effect will depend on customer response and costs. Pricing plans and Q3 results
• Negative Sentiment: Reports say quarterly profit fell and the company reaffirmed its FY26 adjusted EBITDA outlook, tempering the upbeat earnings and growth news. Q3 profit and outlook
• Negative Sentiment: A law firm announced an investigation into potential securities-fraud claims related to product-quality issues. This is an allegation and investigation, not a finding of wrongdoing, but it could add reputational and legal uncertainty. Investigation announcement

About Medline

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.